

Mouse IL-7 ELISA Kit

Catalog Number: RK00379

This ELISA kit used for quantitative determination of Mouse IL-7 concentrations in cell culture supernates, serum and plasma. For research use only, and it's highly recommended to read throughly of this manual before using the product.

Manufactured by

Global Headquarters
500W Cummings Park
Ste. 6500 Woburn, MA 01801

Tel :888-754-5670
E-mail:info@abclonal.com
http: www.abclonal.com

China Branch
388# Gaoxin Road (No.2)
East Lake Development Zone
Wuhan P. R. China

Tel: 400-999-6126
E-mail: market@abclonal.com
http: www.abclonal.com.cn

Contents

Introduction	3
Principle Of The Assay	4
Materials Provided	5
Sample Collection And Storage	6
Precautions For Use	7
Experiment Materials	8
Reagent Preparation.....	9
Wash Method	12
Assay Procedure	12
Assay Procedure Summary	13
Calculation Of Results	15
Typical Data	16
Sensitivity	16
Specificity	17
Precision	18
Recovery.....	20
Linearity Dilute	20
References.....	19

Introduction

Interleukin 7 (IL-7), previously known as pre-B-cell growth factor and lymphopoietin-1, is a type I short-chain cytokine belonging to the hematopoietin family (1-6). Mouse IL-7 is an approximately 25 kDa monomeric glycoprotein that is synthesized as a 154 amino acid (aa) residue precursor with a 25 aa signal sequence and a 129 aa mature segment. Mature mouse IL-7 has six cysteine residues that form three intrachain disulfide bonds, only one of which is required for bioactivity (7). Although multiple alternatively spliced isoforms of human IL-7 that differ in their receptor-binding affinities exist, alternatively spliced isoforms of mouse IL-7 have not been reported (8, 9). Mature mouse IL-7 shares 88% and 65% aa identity with rat IL-7 and human IL-7, respectively (8, 10). Cells known to express IL-7 include Class II MHC positive thymic cortical epithelial cells (11), follicular dendritic cells (12), intestinal epithelium (13), monocytes and keratinocytes (14, 15), endothelial cells (12, 16), vascular smooth muscle cells and fibroblasts (12), and bone marrow stromal cells (17). The high-affinity receptor for IL-7 consists of two type I transmembrane glycoproteins, the ligand-binding IL-7 R α and the non-binding common cytokine gamma chain (γ c), both of which are required for signaling (1, 18, 19). The γ c is a receptor subunit for multiple cytokines including IL-2, IL-4, IL-9, IL-15, and IL-21. IL-7 R α is also shared and is utilized by thymic stromal-derived lymphopoietin (TSLP) in the receptor complex with TSLP receptor. Heparin/heparan sulfate proteoglycans have been shown to bind IL-7 and can regulate the bioavailability and bioactivity of IL-7 (20, 21). IL-7 has a number of lymphocyte-associated activities. In the thymus, IL-7 induces the proliferation of triple negative immature thymocytes, participates in T cell receptor rearrangement, and suppresses CD4 expression in

favor of CD8 on single positive T cells (1). In the periphery, IL-7 contributes to homeostatic proliferation and survival of naive CD4 + and CD8 + T cells (22-24), and promotes the formation and survival of resting memory CD4 + T cells (25, 26) plus the proliferation of memory CD8 + T cells (27). On B cells, IL-7 induces the differentiation of common lymphoid progenitors into CD19 + B cell progenitors (28), and initiates the transition of pro-B cells into early pre-B cells (1). In the intestine, mucosal-derived IL-7 is crucial for both the development of intraepithelial $\gamma\delta$ T cells and the organization of mucosal lymphoid tissue (29). On NK cells, IL-7 induces the proliferation and upregulation of the cytotoxicity of the CD56 bright population of cells (30). This NK cell type is usually known for its cytokine production.

Principle Of The Assay

This assay employs the quantitative sandwich enzyme immunoassay technique. An antibody specific for IL-7 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any IL-7 present is bound by the immobilized antibody. Following incubation unbound samples are removed during a wash step, and then a detection antibody specific for IL-7 is added to the wells and binds to the combination of capture antibody-IL-7 in sample. Following a wash to remove any unbound combination, and enzyme conjugate is added to the wells. Following incubation and wash steps, a substrate is added. A colored product TMB is formed in proportion to the amount of IL-7 present in the sample. The reaction is terminated by addition of acid and absorbance is measured. A

standard curve is prepared from seven IL-7 standard dilutions and IL-7 sample concentration determined.

Materials Provided

Part	Size (96T)	Cat NO.	STORAGE OF OPENED/ RECONSTITUTED MATERIAL
Antibody Coated Plate	8×12	RM01544	Return unused wells to the foil pouch containing the desiccant pack and store at ≤ -20 °C. Reseal along entire edge of zip-seal.
Standard Lyophilized	2	RM01541	Aliquot and store at ≤ -20 °C in a manual defrost freezer.* Avoid repeated freeze-thaw cycles.
Concentrated Biotin Conjugate Antibody (100×)	2 ×60ul	RM01542	May be stored for up to 6 month at 2-8 °C.*
Streptavidin-HRP Concentrated (100×)	2 ×60ul	RM01543	
Standard/Sample Diluent (R1)	1 ×16mL	RM00023	May be stored for up to 6 month at 2-8 °C.*
Biotin-Conjugate Antibody Diluent (R2)	1 ×16mL	RM00024	
Streptavidin-HRP Diluent(R3)	1 ×16mL	RM00025	
Wash Buffer(20×)	1 × 25mL	RM00026	
TMB Substrate	1 ×12 mL	RM00027	

Stop Solution	1 ×12 mL	RM00028	
Plate Sealers	4 strips		
Specification	1		

Sample Collection And Storage

1. Cell Culture Supernates:

Centrifuge 1000x g for 10 min and detect; or aliquot and store samples at -20°C to -70°C (Stored at 2-8°C if tested within 24 hours). Avoid freeze/thaw cycles. If cell culture supernate samples require larger dilutions, perform an intermediate dilution with culture media and the final dilution with the Standard/Sample Diluent(R1).

2. Serum:

Use a serum separator tube and allow samples to clot for 30 minutes before centrifugation for 10 minutes at 1000x g, and detect; or aliquot and store samples at -20°C to -70°C (Stored at 2-8°C if tested within 24 hours). Avoid freeze/thaw cycles.

3. Plasma

Collect plasma using EDTA or heparin as an anticoagulant. Centrifuge for 15 minutes at 1000x g within 30 minutes of collection, and detect; or aliquot and store samples at -20°C to -70°C (Stored at 2-8°C if tested within 24 hours). Avoid freeze / thaw cycles.

4. Avoid hemolytic and hyperlipidemia sample for Serum and Plasma.

5. Dilution:

Dilute samples at the appropriate multiple (recommend to do pre-test to determine the dilution factor).

Precautions

1. **FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.**
2. Any variation in diluent, operator, pipetting technique, washing technique, incubation time or temperature, and kit age can cause variation in binding.
3. Variations in sample collection, processing, and storage may cause sample value differences.
4. Reagents may be harmful, if ingested, rinse it with an excess amount of tap water.
5. Stop Solution contains strong acid. Wear eye, hand, and face protection.
6. Apart from the standard of kits, other components should not be refrigerated.
7. Please perform simple centrifugation to collect the liquid before use.
8. Do not mix or substitute reagents with those from other lots or other sources.
9. Adequate mixing is very important for good result. Use a mini-vortexer at the lowest frequency.
10. Mix the sample and all components in the kits adequately, and use clean plastic container to prepare all of the diluent.
11. Both the sample and standard should be assayed in duplicate, and the sequence of the reagents should be added consistently.
12. Reuse of dissolved standard is not recommended.

13. The kit should not be used beyond the expiration date on the kit label.
14. The kit should be away from light when it is stored or incubated.
15. To reduce the likelihood of blood-borne transmission of infectious agents, handle all serum, plasma and other biological fluids in accordance with NCCLS regulations.
16. To avoid cross contamination, please use disposable pipette tips.
17. Please prepare all the kit components according to the Specification. If the kits will be used several times, please seal the rest strips and preserve with desiccants. Do use up within 2 months.
18. The 48T kit is also suitable for the specification.


Experiment Materials

1. Microplate reader(measuring absorbance at 450 nm, with the correction wavelength set at 570 nm or 630 nm).
2. Pipettes and pipette tips: 0.5-10, 2-20, 20-200, 200-1000 μ L.
3. Microplate washer, Squirt bottle.
4. Micro-oscillator.
5. Deionized or double distilled water, graduated cylinder.
6. Polypropylene Test tubes for dilution.
7. Incubator.

Reagent Preparation

1. **Bring all reagents to room temperature before use. If crystals have formed in the concentrate, Bring the reagent to room temperature and mix gently until the crystals have completely dissolved.**
2. **Standard:** Add Standard/Sample Diluent(R1) 1.0mL into freeze-dried standard, sit for a minimum of 15 minutes with gentle agitation prior to making dilutions (2000pg/mL), Prepare EP tubes containing Standard/Sample Diluent(R1), and produce a dilution series according to the picture shown below (recommended concentration for standard curve: 2000,1000, 500, 250, 125, 62.5, 31.25, 0 pg/mL). Redissolved standard solution (2000 pg/mL), aliquot and store at -20°C— -70°C.

Std 250 μ L 250 μ L 250 μ L 250 μ L 250 μ L 250 μ L



- 3. Concentrated Biotin Conjugate Antibody (100x)** : Dilute 1:100 with the Biotin-Conjugate Antibody Diluent (R2) before use, and the diluted solution should be used within 30 min.

Dilution Method

Strip	Concentrated Biotin-Conjugate antibody (100x)	Biotin-Conjugate Antibody Diluent (R2)
2	20ul	1980ul
4	40ul	3960ul
6	60ul	5940ul
8	80ul	7920ul
10	100ul	9900ul
12	120ul	11880ul

4. **Streptavidin-HRP Concentrated (100x):** Dilute 1:100 with the Streptavidin-HRP Diluent(R3) before use, and the diluted solution should be used within 30 min.

Dilution Method

Strip	Concentrated Streptavidin-HRP (100x)	Streptavidin-HRP Diluent(R3)
2	20ul	1980ul
4	40ul	3960ul
6	60ul	5940ul
8	80ul	7920ul
10	100ul	9900ul
12	120ul	11880ul

5. **Wash buffer:** Dilute 1:20 with double distilled or deionized water before use.

Wash Method


Aspirate each well and wash, repeating the process two times for a total of three washes. Wash by filling each well with **Wash Buffer** (300 μ L) using a squirt bottle, manifold dispenser, or autowasher. Complete removal of liquid at each step is essential to good performance. After the last wash, remove any remaining **Wash Buffer** by aspirating or decanting. Invert the plate and blot it against clean paper towels.

Assay Procedure

1. Remove excess microplate strips from the plate frame, return them to the foil pouch containing the desiccant pack, and reseal.
2. Add wash buffer 300 μ L/well, aspirate each well after holding 40 seconds, repeating the process three times for a total of four washes.
3. Add 100 μ L Standard/sample Diluent (R1) in blank well.
4. Add 100 μ L different concentration of standard and sample in other wells, cover with the adhesive strip provided. Incubate for 1.5 hours at 37°C.
5. Repeat the aspiration/wash as in step 2.
6. Prepare the Concentrated Biotin Conjugate Antibody (100X) Working Solution 15 minutes early before use.
7. Add Biotin-Conjugate antibody Working Solution in each wells (100 μ L/well), cover with new adhesive strip provided. Incubate for 1 hour at 37°C.

8. Prepare the Streptavidin-HRP Concentrated (100X) Working Solution 15 minutes early before use.
9. Repeat the aspiration/wash as in step 2.
10. Add Streptavidin-HRP Working Solution in each wells (100 μ L/well), cover with new adhesive strip provided. Incubate for 30 minutes at 37°C.
11. Warm-up the Microplate reader.
12. Repeat the aspiration/wash as in step 2.
13. Add TMB Substrate (100 μ L/well). Incubate for 15-20 minutes at 37°C. Protect from light.
14. Add Stop Solution (100 μ L/well), determine the optical density of each well within 5 minutes, using a Microplate reader set to 450 nm. If wavelength correction is available, set to 570 nm or 630 nm. If wavelength correction is not available, subtract readings at 570 nm or 630 nm from the readings at 450 nm. This subtraction will correct for optical imperfections in the plate. Readings made directly at 450 nm without correction may be higher and less accurate.

Assay Procedure Summary



Add 100ul Biotin-Conjugate antibody Working Solution

Incubate for 1 hour at 37°C

wash 4 times

Add 100ul Streptavidin-HRP Working Solution

Incubate for 30 min at 37°C

wash 4 times

Add 100ul Substrate Solution

Incubate for 15-20 min

at 37°C under dark condition.

Add 100ul Stop Solution


Detect the optical density within 5 minutes under 450nm.

Correction Wavelength set at 570nm or 630nm

Calculation Of Results

1. Average the duplicate readings for each standard, control and sample, and subtract the average zero standard optical density (O.D.).
2. Create a standard curve by reducing the data using computer software capable of generating a log/log curve-fit. As an alternative, construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis and draw a best fit curve through the points on a log/log graph. The data may be linearized by plotting the log of the IL-7 concentrations versus the log of the O.D. on a linear scale, and the best fit line can be determined by regression analysis.
3. If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.

Typical Data



The standard curves are provided for demonstration only. A standard curve should be generated for each set of IL-7 assayed.

Sensitivity

The minimum detectable dose (MDD) of IL-7 is typically less than 15 pg/mL. The MDD was determined by adding two standard deviations to the mean optical density value of twenty zero standard replicates and calculating the corresponding concentration.

Specificity

This assay recognizes both recombinant and natural mouse IL-7. The factors listed below were prepared at 50ng/ml and assayed for cross-reactivity. No significant cross-reactivity was observed with the following:

Recombinant mouse	Recombinant human
-------------------	-------------------

IL-1 α	IL-7
---------------	------

IL-1 β	
--------------	--

IL-2	
------	--

IL-3	
------	--

IL-4	
------	--

IL-5	
------	--

IL-6	
------	--

IL-7 R α	
-----------------	--

IL-9	
------	--

IL-10	
-------	--

IL-11	
-------	--

IL-12	
-------	--

IL-12/IL-23 p40	
-----------------	--

IL-15	
-------	--

IL-17	
-------	--

IL-18	
-------	--

IL-21	
-------	--

IL-22	
-------	--

TSLP	
------	--

IL-13

Precision

Intra-plate Precision

Repeat 20 times detection of 3 known concentration sample enzyme plate to evaluate the Intra-plate precision.

Sample	1	2	3
Repeat Times	20	20	20
Average Value (pg/mL)	65	315	640
Standard Deviation (SD)	2.0	11.0	19.8
Variable Coefficient CV (%)	3.2	3.5	3.1

Inter-plate Precision

Repeat 20 times detection of 3 known concentration sample enzyme plate to evaluate the Inter-plate precision.

Sample	1	2	3
Repeat Times	20	20	20
Average Value (pg/mL)	70	360	730
Standard Deviation (SD)	4.5	20.1	52.5
Variable Coefficient CV (%)	6.5	5.6	7.2

Recovery

Aspirate 3 different concentration of mouse IL-7 into healthy human serum and plasma, calculate the recovery.

Sample Form	Average Recover (%)	Range (%)
Serum	98	90-113
Plasma	103	86-105

Linearity Dilute

Aspirate high concentration of mouse IL-7 into 4 healthy human serum, dilute in the range of standard curve kinetics and evaluate the linearity.

Dilution	Average Value (%)	Range (%)
1:2	101	86-113
1:4	102	82-106
1:8	102	91-109
1:16	101	83-110

References

1. Fry, T.J. and C.L. Mackall (2002) Blood 99:3892.
2. Appasamy, P.M. (1993) Cancer Invest. 11:487.
3. Lupton, S.D. et al. (1990) J. Immunol. 144:3592.
4. Namen, A.E. et al. (1988) Nature 333:571.
5. VanderSpek, J.C. et al. (2002) Cytokine 17:227.
6. Kroemer, R.T. et al. (1996) Protein Eng. 9:493.
7. Cosenza, L. et al. (1997) J. Biol. Chem. 272:32995.
8. Goodwin, R.G. et al. (1989) Proc. Natl. Acad. Sci. USA 86:302.
9. Kroemer, R.T. et al. (1998) Protein Eng. 11:31.
10. Widegren, B. et al. (2000) GenBank Accession #:P56478.
11. Oosterwegel, M.A. et al. (1997) Immunity 6:351.
12. Kroncke, R. et al. (1996) Eur. J. Immunol. 26:2541.
13. Watanabe, M. et al. (1995) J. Clin. Invest. 95:2945.
14. Sieling, P.A. et al. (1995) J. Immunol. 154:2775.
15. Heufler, C. et al. (1993) J. Exp. Med. 178:1109.
16. Roye, O. et al. (1998) J. Immunol. 161:4161.
17. Funk, P.E. et al. (1995) Blood 86:2661.
18. Noguchi, M. et al. (1993) Science 262:1877.
19. Goodwin, R.G. et al. (1990) Cell 60:941.
20. Borghesi, L.A. et al. (1999) Blood 93:140.
21. Clarke, D. et al. (1995) Cytokine 7:325.
22. Schluns, K.S. et al. (2000) Nat. Immunol. 1:426.
23. Boursalian, T.E. and K. Bottomly (1999) J. Immunol. 162:3795.
24. Tan, J.T. et al. (2001) Proc. Natl. Acad. Sci. USA 98:8732.

- 25. Kondrack, R.M. et al. (2003) J. Exp. Med. 198:1797.**
- 26. Li, J. et al. (2003) J. Exp. Med. 198:1807.**
- 27. Tan, J.T. et al. (2002) J. Exp. Med. 195:1523.**
- 28. Miller, J.P. et al. (2002) J. Exp. Med. 196:705.**
- 29. Laky, K. et al. (2000) J. Exp. Med. 191:1569.**
- 30. Dadmarz, R. et al. (1994) Lymphokine Cytokine Res. 13:349.**